Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; Evidence in support of drug resistance: Insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials

EuroIntervention

Volumn 9, Issue 7, 2013, Pages 797-802

  Byrne, Robert A ^a   Cassese, Salvatore ^a   Windisch, Thomas ^a   King, Lamin A ^a   Joner, Michael ^a   Tada, Tomohisa ^a   Mehilli, Julinda ^a   Pache, Jürgen ^a   Kastrati, Adnan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Drug resistance; Drug eluting stent; Hyporesponsiveness; Paclitaxel; Restenosis; Sirolimus

Indexed keywords

PACLITAXEL; RAPAMYCIN; METAL;

ADULT; AGED; ANTIRESTENOTIC ACTIVITY; ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; CORONARY ANGIOGRAPHY; DRUG ACTIVITY; DRUG RESISTANCE; FEMALE; FOLLOW UP; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PREDICTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); CORONARY RESTENOSIS; DRUG ELUTING STENT; TREATMENT OUTCOME;

CORONARY RESTENOSIS; DRUG RESISTANCE; DRUG-ELUTING STENTS; HUMANS; METALS; PACLITAXEL; SIROLIMUS; TREATMENT OUTCOME;

EID: 84979864757     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV9I7A132     Document Type: Article

References (15)

1. Byrne RA, Sarafoff N, Kastrati A, Schomig A. Drug-eluting stents in percutaneous coronary intervention: A benefit-risk assessment. Drug Saf. 2009;32:749-70.
2. Kastrati A, Byrne R. New roads, new ruts: Lessons from drug-eluting stent restenosis. JACC Cardiovasc Interv. 2011;4:165-7.
3. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56:1897-907.
4. Byrne RA, Joner M, Massberg S, Kastrati A. Restenosis in bare metal and drug-eluting stents. In: Escaned J, Serruys PW, (eds). Coronary Artery Stenosis: Imaging, structure and physiology. Toulouse, France: PCR Publishing; 2010.
5. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schuhlen H, Schmitt C, Dirschinger J, Schomig A. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: A randomized controlled trial. JAMA. 2005;293:165-71.
6. Mehilli J, Byrne RA, Tiroch K, Pinieck S, Schulz S, Kufner S, Massberg S, Laugwitz KL, Schomig A, Kastrati A. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: The ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol. 2010;55:2710-6.
7. Mehilli J, Kastrati A, Wessely R, Dibra A, Hausleiter J, Jaschke B, Dirschinger J, Schömig A. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation. 2006;113:273-9.
8. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB. Angiographic patterns of in-stent restenosis: Classification and implications for long-term outcome. Circulation. 1999;100:1872-8.
9. Alfonso F, Pérez-Vizcayno MJ, Dutary J, Zueco J, Cequier A, García-Touchard A, Martí V, Lozano I, Angel J, Hernández JM, López-Mínguez JR, Melgares R, Moreno R, Seidelberger B, Fernández C, Hernandez R; RIBS-III Study Investigators (under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology). Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]). JACC Cardiovasc Interv. 2012;5:728-37.
10. Cosgrave J, Melzi G, Corbett S, Biondi-Zoccai GG, Babic R, Airoldi F, Chieffo A, Sangiorgi GM, Montorfano M, Michev I, Carlino M, Colombo A. Repeated drug-eluting stent implantation for drug-eluting stent restenosis: The same or a different stent. Am Heart J. 2007;153:354-9.
11. Garg S, Smith K, Torguson R, Okabe T, Slottow TL, Steinberg DH, Roy P, Xue Z, Gevorkian N, Satler LF, Kent KM, Suddath WO, Pichard AD, Waksman R. Treatment of drug-eluting stent restenosis with the same versus different drug-eluting stent. Catheter Cardiovasc Interv. 2007;70:9-14.
12. Kurmasheva RT, Huang S, Houghton PJ. Predicted mechanisms of resistance to mTOR inhibitors. Br J Cancer. 2006;95:955-60.
13. Huang S, Houghton PJ. Mechanisms of resistance to rapamycins. Drug Resist Updat. 2001;4:378-91.
14. Byrne R, Iijima R, Mehilli J, Pache J, Schulz S, Schomig A, Kastrati A. Treatment of Paclitaxel-eluting stent restenosis with sirolimus-eluting stent implantation: Angiographic and clinical outcomes. Rev Esp Cardiol. 2008;61:1134-9.
15. Steinberg DH, Gaglia MA Jr, Pinto Slottow TL, Roy P, Bonello L, De Labriolle A, Lemesle G, Torguson R, Kineshige K, Xue Z, Suddath WO, Kent KM, Satler LF, Pichard AD, Lindsay J, Waksman R. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents. Am J Cardiol. 2009;103:491-5.